Abstract
BackgroundImmune checkpoint inhibitors (ICIs) benefit patients with multiple cancer types, however, additional predictive biomarkers of response are needed. CD274 (programmed cell death ligand-1, PD-L1) gene rearrangements are positively associated with...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have